Source title: 2022 national medical insurance negotiations concluded, there are a rich variety of new crown treatment drugs in medical insurance
Yesterday (January 8) the four-day negotiations on the 2022 national medical insurance drug list were concluded in Beijing. The number of drugs in this medical insurance negotiation is large, including innovative drugs such as anticancer drugs and drugs for rare diseases, as well as drugs for the treatment of new crowns whose final results should be announced in the near future.
Compared to the previous two years, the number of drugs participating in this medical insurance negotiation has increased significantly: A total of 343 drugs have passed formal review, including 198 new drugs added off-list and 145 renewed drugs in the list. During the four trading days, the first day focused on antiviral, respiratory and anesthetic drugs; the sixth focused on drugs for cardiovascular, orthopedic and immune diseases; One of the key points; last-day negotiations were mainly Chinese patent drugs.
This year, two new rules initiated by the national medical insurance negotiations have attracted a lot of attention. Among them, “simple renewal” means that the agreement expires on December 31, 2022 and drugs that meet the five conditions of Exclusive Drugs and the fact that the actual spending of the fund during the agreement period does not exceed 200% of the budget can undergo a simple renewal. Industry experts believe this will help streamline the negotiation process and improve the efficiency of contract renewal. The “non-exclusive drug offer” refers to the drug placed on the drug list by offer, and the lowest price among various companies’ quotes is taken as the payment standard for the generic drug. This means that if a pharmaceutical company participating in the “non-exclusive drug offering” offers a lower price, other pharmaceutical companies will also enter the medical insurance at a lower price.
Cancer drugs and rare disease drugs are the focus of this medical insurance deal, in which 6 PD-1 cancer drugs and 19 rare disease drugs are participating. Experts said that in recent years more and more innovative drugs have participated in medical insurance negotiations: on the one hand, more people can use good drugs as soon as possible.
As for the widely followed COVID-19 treatment drugs, the head of the medical management department of the National Medical Insurance Bureau said on the 8th that the three drugs that entered the negotiation, Azvudine Tablets and Qingfei Paidu Granules , were successfully negotiated, and Pfizer Naimatevir tablets/Lito Navir tablets combo pack failed due to high quotations. After negotiation, there are more than 600 kinds of medicines for the treatment of fever, cough and other new corona symptoms in the National Medical Insurance Drug List.
Four departments, including the National Medical Insurance Bureau, have clarified that the temporary medical insurance payment policy will be implemented for the new corona treatment drugs included in the new corona diagnosis and treatment plan and will be implemented until 31 March 2023. Recently, the local medical insurance departments also temporarily included a batch of new drugs for the symptomatic treatment of corona under the medical insurance payment in the region according to local conditions. Overall, there are a wide variety of drugs to treat new coronavirus infections that are reimbursed by medical insurance. In the next step, the National Medical Insurance Administration will do its best to adjust the medical insurance drug list and include more new and valid drugs in the medical insurance drug list, so as to effectively reduce the burden of medical care for the masses.
